Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

HONG KONG, Oct 14, 2025 – (ACN Newswire)– Everest Medicines today revealed that the very first client has actually been registered in an international multi-center Phase I medical trial of its Tumor-Associated Antigen Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States. Formerly, the Investigational New Drug (IND) application for EVM14 has actually been authorized by the National Medical Products Administration (NMPA) in China. EVM14 ends up being Everest Medicines’ very first internally established restorative mRNA cancer vaccine to get IND approvals from both China’s NMPA and the U.S. Food and Drug Administration (FDA).

EVM14, an off-the-shelf healing mRNA cancer vaccine, is established based upon Everest Medicines’ proprietary mRNA platform. It is developed with mRNA encoding 5 tumor-associated antigens (TAAs) and is created to deal with numerous squamous cell cancers, consisting of squamous non-small cell lung cancer (sq-NSCLC) and head and neck squamous cell cancer (HNSCC). In the targeted cancer types, 96% of clients with sq-NSCLC and 97% of clients with HNSCC revealed a minimum of among the 5 target genes[1]TTA vaccines provide unique benefits, consisting of removal of HLA screening requirements, off-the-shelf accessibility, lower production expenses versus customized neoantigen vaccines, and applicability throughout several growth types.

“The cancer concern in China stays significant. Neither immunotherapy nor targeted treatment can use long term advantages to cancer clients. EVM14 is developed to deal with numerous squamous cell cancers, EVM14’s distinct system provides the possible to match existing treatments by boosting the effectiveness by means of mix treatments and assisting hold-up illness reoccurrence, lining up with present patterns in oncology drug advancement.” stated Professor Lu Shun, the Lead Principal Investigator in China and Director of the Oncology Department at Shanghai Chest Hospital.

“The registration of the very first client with EVM14 in the United States marks a crucial accomplishment ahead of time the worldwide medical advancement of our in-house mRNA platform.” stated Rogers Yongging Luo, Chief Executive Officer of Everest Medicines. “This development shows Everest’s ongoing efforts to equate technological development into medical practice and our very first relocation benefit in establishing next-generation immuno-oncology treatments, consisting of restorative mRNA cancer vaccines. EVM14 is Everest’s very first healing mRNA cancer vaccine to attain IND approvals in both China and the U.S. The big client population deals with minimal choices with existing standard-of-care treatments, highlighting an unmet medical requirement. As a TAA cancer vaccine, EVM14’s special system provides the prospective to match present treatments by boosting the effectiveness through mix treatments and assisting hold-up illness reoccurrence, using expect long-lasting cancer-free survival. With EVM14 getting IND approval from China’s NMPA, we eagerly anticipate this ingenious treatment showing appealing healing capacity in international multicenter scientific trials, bringing more treatment alternatives to clients around the world and improve their lifestyle.”

Everest Medicines’ Jiashan production website launched the very first GMP scientific trial batch in June 2025. This batch will support the medical trials of EVM14 in both China and the United States. The scientific centers involved consist of NEXT Oncology Virginia, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center in the U.S., and Shanghai Chest Hospital in China.

Leveraging the business’s industry-leading mRNA restorative cancer vaccine platform and mRNA in vivo CAR-T platform, it is constructing a worldwide competitive R&D pipeline. EVM18, the in vivo CAR-T program, has actually finished several non-human primates (NHPs) trials and accomplished preclinical proof-of-concept, with first-in-human information anticipated to start by the end of 2025. EVM16, the customized healing mRNA cancer vaccine, has actually started its first-in-human trial in China, with client dosing finished. In the investigator-initiated trial (IIT), dosage escalation in the low- and mid-dose accomplices has actually been finished, with motivating initial information observed. EVM15, the immune-modulatory cancer vaccine, has actually finished preclinical evidence of idea and determined its scientific prospect.

Looking ahead, Everest Medicines will continue to deepen its “dual-engine” method, keeping a strong concentrate on advancing ingenious drug discovery and advancement to drive sustainable development and international growth. The Company stays dedicated to providing ingenious treatments to clients, developing long-lasting worth for investors, and driving forward with the vision of ending up being a leading worldwide biopharmaceutical business.

Subject: Clinical Trial Results